Form 4: Collegium Pharmaceutical Director Nancy Lurker Acquires Shares Through Restricted Stock Units

Director Nancy Lurker received 12,726 restricted stock units (RSUs) convertible to common stock in Collegium Pharmaceutical, Inc.

Summary

• Nancy Lurker, a director of Collegium Pharmaceutical, Inc., acquired 12,726 shares of common stock on February 4, 2025.
• The acquisition was in the form of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on February 4, 2026, contingent upon Lurker's continued service with the company.
• The RSUs will be settled in shares of Collegium Pharmaceutical's common stock on the vesting date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs to a director is a common practice and suggests confidence in the company's future. There are no explicitly negative indicators.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.
• The vesting requirement of continued service aligns the director's interests with those of the shareholders.

Future Outlook

The document indicates that Nancy Lurker will receive shares of Collegium Pharmaceutical common stock on February 4, 2026, if she continues to serve as a director.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Stakeholder Impact

• Shareholders may view the RSU grant positively, as it aligns the director's interests with the company's long-term success.
• Employees may see the RSU grant as a sign of the company's commitment to its leadership.

Key Dates

Keywords

RSU, Director, Collegium Pharmaceutical, Stock Acquisition, Form 4, Nancy Lurker, Beneficial Ownership